Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Novartis AG Sponsored ADR
NVS
$150.44 (+ $0.83 + 0.55%)
Last updated: Previous Close (2026-05-19)
About the Company
Novartis AG Sponsored ADR represents the American Depositary Receipts of Novartis AG, a Swiss-based innovative medicines company headquartered in Basel. This ADR enables U.S. investors convenient access to Novartis AG shares, facilitating liquidity and exposure to global pharmaceutical innovation. Novartis AG focuses on researching, developing, producing, distributing, and commercializing advanced treatments across key therapeutic areas, including oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases, and respiratory conditions. Its portfolio features prominent products such as Entresto and Leqvio in cardiovascular; Cosentyx, Xolair, and Ilaris in immunology; Kesimpta, Zolgensma, and Mayzent in neuroscience; and oncology offerings like Kisqali, Pluvicto, Lutathera, Kymriah, and Scemblix. Additionally, established brands like Lucentis and Sandostatin support ongoing patient care. Operating as a single global segment post its generics spin-off, Novartis AG delivers medicines worldwide, emphasizing research-driven solutions that address serious diseases and enhance healthcare accessibility. Founded in 1996, the company maintains a significant presence in the healthcare sector through its broad therapeutic expertise.
Price History
Latest News for NVS
Tesla, SMCI, Others See Sharp Analyst Revisions
Sentiment shifts as risks and opportunities emerge
There Are Three Things Driving Amplify’s 5.1%. Yield Higher | IDVO
Most income ETFs draw from a single well: either dividends or options premium. The Amplify CWP International Enhanced Dividend Income ETF (NYSEARCA:IDVO) draws from three simultaneously, and the way it selects holdings is what separates it from passive income funds. The fund targets American Depositary Receipts, the dollar-denominated securities that let U.S. investors own shares ... There Are Three Things Driving Amplify’s 5.1%. Yield Higher | IDVO
Health Care Roundup: Market Talk
1127 ET – Novartis’s share-price strength this year raises the bar for upcoming data on late-stage clinical studies that will be pivotal for the Swiss drugmaker’s outlook, Bank of America analysts say in a research note. Pipeline failure could hit consensus estimates, but success would help shift investors’ focus away from patent expirations, according to Bank of America. Among Novartis’s upcoming phase 3 trials, Bank of America is most focused on remibrutinib in relapse-remitting multiple sclerosis and pelacarsen in secondary prevention of cardiovascular events, the analysts say.
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasisAdditional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s Ame
Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut
Voyager Therapeutics (NASDAQ:VYGR) CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer blood-brain barrier (BBB)-penetrant capsid platform. Sandrock described 2026 as “the year of tau,” while also pointing to upcoming clinical
Stocks to Watch Recap: Super Micro Computer, FedEx, Unilever
↗️ FedEx (FDX): The shipping company raised its outlook as revenue increased in the fiscal third quarter. Shares rose 0.8%. ↘️ Super Micro Computer (SMCI): The technology company placed two employees on leave and fired a contractor after learning of their alleged involvement in a scheme to divert computer servers assembled in the U.